The robustness of our preclinical findings, along with promising early clinical data, prompted this study to explore the association between TAZ, evaluated in diagnostic core biopsies, and pathological complete response (pCR) in HER2-positive BC patients treated with trastuzumab-based neoadjuvant therapy. The gene discussed is ERBB2; the disease is breast cancer.